Published in final edited form as:

Drug Metabol Drug Interact. 2008 ; 23(1-2): 125–150.

Protein and nucleotide damage by glyoxal and methylglyoxal in physiological systems - role in ageing and disease

Paul J. Thornalley

Protein Damage and Systems Biology Research Group, Clinical Sciences Research Institute, Warwick Medical School, University of Warwick, University Hospital, Coventry CV2 2DX, United Kingdom

Abstract

Glycation of proteins, nucleotides and basic phospholipids by glyoxal and methylglyoxal – physiological substrates of glyoxalase 1 - is potentially damaging to the proteome, genome and lipidome. Glyoxalase 1 suppresses glycation by these α -oxoaldehyde metabolites and thereby represents part of the enzymatic defence against glycation. Albert Szent-Gyorgyi pioneered and struggled to understand the physiological function of methylglyoxal and the glyoxalase system. We now appreciate glyoxalase 1 protects against dicarbonyl modifications of the proteome, genome and lipome. Latest research suggests there are functional modifications of this process – implying a role in cell signalling, ageing and disease.

Letter from Albert Szent-Gyorgyi

“I thank you for your kind lines from May 17th, and the reprints that reached me only now. It was very long ago that I was interested in keto-aldehydes and worked on them. Since then I forgot most of what I knew. So, to my regret I am unable to advise you. Yours truly, Albert Szent-Gyorgyi, MD, PhD, NL.” From a letter to the author dated 7th June 1984.

Above are the words of Albert Szent-Gyorgyi in a letter replying to my request for advice on how to pursue a research career on studies of methylglyoxal and the glyoxalase system. The letter was sent from the National Foundation for Cancer Research, Woods Hole, Massachusetts, USA. It has been framed, along side newspaper obituary tributes to Szent-Gyorgyi when he died in October 1986, hanging in my office for over the last 20 years whilst I grappled with similar problems that once interested him. Our common interest was, for Szent-Gyorgyi, and still is for me the physiological significance of the glyoxalase system and its physiological substrates – primarily the reactive dicarbonyl compounds and physiological metabolites, glyoxal and methylglyoxal /1,2/ – Figure 1.

Methylglyoxal and glyoxal – physiological substrates of the glyoxalase system

The presence and significance of reactive acyclic α -oxoaldehydes, methylglyoxal and glyoxal, in physiological systems was the subject of research before, during and after the research career of Szent-Gyorgyi. Neuberg had discovered the glyoxalase system and metabolism of methylglyoxal in 1913 /3/. Szent-Gyorgyi advanced his hypothesis of the “retine and promine” theory of control of cell proliferation /1/, and recent research views

glyoxalase 1 (Glo1) as part of the enzymatic defence against glycation /2/. Methylglyoxal has been considered to be an environmental and/or bacterial toxin and metabolite /4,5/. We now know methylglyoxal is formed spontaneously from triosephosphates in all organisms with anaerobic glycolysis /6/ and from other non-enzymatic and enzymatic pathways of differing significance – depending on the organism /7/. Glyoxal is formed by lipid peroxidation and the degradation of monosaccharides, saccharide derivatives and glycated proteins /8,9/. A continuing problem in the area of research is reliable estimation of the concentrations of methylglyoxal and glyoxal in physiological systems. Both of these compounds may be formed by degradation of monosaccharides, glycated proteins, glycolytic intermediates – and indeed from degradation of derivatising agents – during sample processing for estimation of their concentrations in physiological samples. As a consequence, physiological concentrations of methylglyoxal and glyoxal have often been overestimated. Chemical derivatisation of α -oxoaldehydes is essential for assay to adequate sensitivity. Some analytical methods used to estimate physiological concentrations of methylglyoxal and glyoxal (and other α -oxoaldehydes) are given in Table 1. The latest and most advanced methods employ derivatisation with 1,2-diaminobenzene and detection by gas chromatography with mass spectrometric detection (GC-MS) /10/ or liquid chromatography with tandem mass spectrometric detection (LC-MS/MS) with stable isotopic dilution analysis /11/. Recent estimates of the concentrations of methylglyoxal and glyoxal in human blood plasma are in the range 100 – 120 nM /12,13/ and cellular concentrations of methylglyoxal (1 – 5 μ M) and glyoxal (0.1 – 1 μ M) /11/. With inadequate control of interferences during sample processing, estimates of 10 – 1000-fold higher than this may be easily recorded. Studies investigating the effects of glyoxal and methylglyoxal on cultured cells and tissues using at concentrations > 10-fold higher than this are likely to be only of relevance for acute intoxication and cytotoxicity. The use of methylglyoxal at millimolar concentrations to demonstrate impairment of insulin signalling, for example, is of unlikely physiological relevance /14/. For studies investigating the effects of increased methylglyoxal concentrations, it is more appropriate to increase endogenous methylglyoxal concentrations by inhibition of Glo1 with specific cell permeable inhibitors – such as *S*-p-bromobenzylglutathione cyclopentyl diester (SpBrGSHCp₂) /15/ or decrease Glo1 by siRNA techniques /16/.

Modification of proteins by glyoxal and methylglyoxal

Glyoxal and methylglyoxal are potent glycating agents. Glycation of proteins is a complex series of parallel and sequential reactions collectively called the Maillard reaction. It occurs in all tissues and body fluids. Early stage reactions in glycation of protein by glucose lead to the formation of fructosyl-lysine (FL) and *N*-terminal amino acid residue-derived fructosamines. Later stage reactions form stable end-stage adducts called advanced glycation endproducts (AGEs) /17/. FL degrades slowly to form AGEs – and also glyoxal and methylglyoxal /9/. In contrast, glyoxal and methylglyoxal react with proteins to form AGE residues directly and relatively rapidly. For example, addition of 1 μ M [¹⁴C]methylglyoxal to human plasma *ex vivo* and incubated at 37 °C produced complete and irreversible binding of methylglyoxal to plasma protein within 24 h /18/. Important AGEs quantitatively are hydroimidazolones derived from arginine residues modified by glyoxal and methylglyoxal – *N*₆-(5-hydro-4-imidazolone-2-yl)ornithine (G-H1) and *N*₆-(5-hydro-5-methyl-4-imidazolone-2-yl)-ornithine (MG-H1) /19,20/; there are also related structural isomers /21/. There is concurrent formation of minor lysine-derived adducts – *N*_ε-carboxymethyl-lysine (CML) and *N*_ε-carboxyethyl-lysine (CEL) residues, and bis(lysyl) crosslinks – GOLD and MOLD /21,22/. For glyoxal, there is a further minor arginine-derived adduct formed – *N*_ω-carboxymethylarginine (CMA) /23/; the corresponding methylglyoxal-derived adduct, *N*_ω-carboxyethylarginine, is unstable and not detected. For methylglyoxal, there is a trace fluorescent adduct formed called argpyrimidine /24,25/. Hydroimidazolones have relatively

moderate half-lives (2 – 6 weeks) and slow dynamic reversibility; therefore, protein content of hydroimidazolones can be decreased if the concentrations of the precursor α -oxoaldehydes are decreased /19,21/. Where hydroimidazolones accumulate with donor age, the increase is related to decreased activity of Glo1 and increased methylglyoxal concentration /26,27/ – Figure 2a.

Protein glycation was viewed originally as a post-translational modification that accumulated mostly on extracellular proteins. Specifically, AGEs were thought to be formed slowly throughout life and the concentrations of AGEs found represent a life-long accumulation of the glycation adduct. This applies to chemically stable AGEs formed on long-lived proteins. For example, CML and CEL residue accumulation on skin collagen /28,29/. Hydroimidazolones have relatively short chemical half-lives under physiological conditions (2 – 6 weeks), however, and their concentration depends on the balance of the rates of formation and decomposition. Moreover, protein glycation adduct residues are also formed on cellular and short-lived extracellular proteins. The turnover of these proteins by cellular proteolysis releases glycation free glycation adducts (glycated amino acids) /19/. Protein damage by glycation is implicated in protein misfolding. Misfolded proteins are degraded by the proteasome to ensure the high quality of intracellular proteins /30/; the median half-life of cellular proteins was 32 h /31/. Protein glycation free adducts are, therefore, the excreted debris of cellular proteolysis of damaged proteins. This appears to be an efficient process since there was little evidence of low molecular mass damaged peptides in peripheral venous plasma. Additional sources of free adducts are direct glycation of lysine and arginine. This probably plays a minor contribution because of the relatively low concentration of free amino acids compared to the concentration of corresponding amino acid residues in proteins /19/.

Saccharide-rich and thermally processed foods are a good source of AGE residues /32/. There is a low bioavailability of AGE residues in proteins of ingested foods such that <10% is absorbed /33/ – attributed to resistance to proteolysis of highly glycated proteins in food /22/ and some AGEs inhibit intestinal proteases /34/. The highest concentration of absorbed food AGEs is expected in portal venous plasma where we found the hydroimidazolone MG-H1 enriched by 10-fold in peptides /35/. AGEs are therefore probably absorbed from food as both AGE free adducts and AGE-rich peptides; the latter appear to be degraded efficiently after absorption. Hydroimidazolones G-H1 and MG-H1, CML and CEL free adducts had high renal clearances /19/. This suggests that as long as renal function is normal, protein glycation and oxidation adducts absorbed from food may pose little threat – although this remains controversial /36/ – Figure 3.

Proteins in mammalian tissues, plasma and extracellular matrix *in vivo* have relatively high MG-H1 residue content (0.1 – 15 mmol/mol amino acid modified), much lower CML and CEL residue content (0.05 – 6 mmol/mol lys) and trace amounts of GOLD and MOLD residues (0.001 – 0.002 mmol/mol lys) - depending on the protein substrate and tissue location, type of AGE. Hydroimidazolone AGEs are found in highest concentrations in lens protein of elderly human subjects; MG-H1 residue content was 1 – 2% of total arginine residues. Stable AGEs such as CML residues accumulate on lens capsule, skin and cartilage collagen with age but reached <6 mmol/mol lys in cartilage in old age /28,37/.

The physiological importance of protein glycation remains under intensive investigation. Particularly damaging effects are produced by covalent crosslinking of proteins which confers resistance to proteolysis /38/. Protein modification is also damaging when amino acid residues are located in sites of protein-protein interaction, enzyme-substrate interaction and protein-DNA interaction (for transcription factors). A bioinformatics analysis of receptor binding domains indicated that arginine residues have the highest probability of

being located in such sites (19.6%) /39/. The major modification of proteins by glyoxal and methylglyoxal is on arginine residues. Formation of hydroimidazolones causes structural distortion, loss of side chain charge and functional impairment /25/. Two examples we studied recently are methylglyoxal modification of human serum albumin and vascular type IV collagen.

Modification of human serum albumin by methylglyoxal produced hotspot modification of Arg-410 with hydroimidazolone MG-H1 residue formation. Modification of Arg-410 by methylglyoxal was found in albumin glycated *in vivo*. Arg-410 is located in drug binding site II and the active site of albumin-associated esterase activity. Hydroimidazolone formation at Arg-410 inhibited drug binding and esterase activity. Molecular dynamics and modelling studies indicated that hydroimidazolone formation caused structural distortion leading to disruption of arginine-directed hydrogen bonding and loss of electrostatic interaction /25/. MG-H1 residue formation in albumin and other plasma proteins was increased in clinical diabetes and end stage renal disease /20,40/.

Modification of vascular basement membrane type IV collagen by methylglyoxal formed MG-H1 residues at hotspot modification sites in RGD and GFOGER integrin-binding sites of collagen, causing endothelial cell detachment, anoikis and inhibition of angiogenesis. Endothelial cells incubated in model hyperglycaemia *in vitro* and experimental diabetes *in vivo* produced the same modifications of vascular collagen, inducing similar responses. Increased methylglyoxal formed from triosephosphate degradation within endothelial cell crossed the plasma membrane and modified type IV collagen /11/. This may contribute to increased shedding of vascular endothelial cells and increased numbers of circulating endothelial cells in diabetes and uraemia where plasma levels of methylglyoxal and other α -oxoaldehydes are abnormally high /41,42/. The number of circulating endothelial cells, indicative of damage to the endothelium, is prognostic for vascular disease /43/.

Glycation of proteins by glyoxal and methylglyoxal is not only common in mammalian systems. MG-H1 hydroimidazolone has been isolated from bacteria /44/ and we have recently found glyoxal and methylglyoxal-derived AGE residues in proteins of higher plants with variation in light and dark growth cycles /45/.

Modification of nucleotides by glyoxal and methylglyoxal

DNA is susceptible to glycation by glyoxal and methylglyoxal - the nucleotide most reactive under physiological conditions is deoxyguanosine (dG). Under conditions of limiting α -oxoaldehyde, as applies *in vivo*, the major nucleotide AGEs are the imidazopurinone derivatives 3-(2'-deoxyriboseyl)-6,7-dihydro-6,7-dihydroxyimidazo[2,3-b]purine-9(8)one (dG-G) derived from glyoxal /46/ and 3-(2'-deoxyriboseyl)-6,7-dihydro-6,7-dihydroxy-6-methylimidazo-[2,3-b]purine-9(8)one (dG-MG) derived from methylglyoxal /47,48/. Other adducts, N_2 -carboxymethyl-deoxyguanosine (CMdG) and 5-glycolyldeoxycytidine (gdC) derived from glyoxal /46/, and N_2 -(1-carboxyethyl)-deoxyguanosine (CEdG) derived from methylglyoxal /47,48/ have been reported – Figure 2b. These are called nucleotide advanced glycation endproducts (nucleotide AGEs). There have been few quantitative estimates of nucleotide AGEs in mammalian cells. dG-G and dG-MG are unstable at high pH and temperatures and hence DNA extraction and hydrolysis for analysis of these DNA adducts must avoid such conditions. In recent studies, we developed an LC-MS/MS assay methodology using acid nuclease digestion and isotopic dilution analysis. Estimates of imidazopurinone adducts and the major oxidative adduct of DNA, 8-hydroxydeoxyguanosine (8-HO-dG), in human mononuclear leukocytes were (adducts per 10^6 nucleotide; n = 3): dG-G 1.59 ± 0.08 ; dG-MG 15.7 ± 0.38 and 8-HO-dG 3.33 ± 0.13 /49/. This suggests that glycation by glyoxal and methylglyoxal is an important type of

damage quantitatively of DNA *in vivo*. DNA suffers continuous damage from glycation by methylglyoxal and glyoxal. Imidazopurinones have only moderate stability under physiological conditions but are stabilized by formation in single- and double-stranded DNA: half-lives for dG-G and residues in single- and double-stranded DNA were 14.8 h, 285 h and 595 h at pH 7.4 and 37°C, respectively. The formation of CEdG was associated with depurination of DNA /50/.

The presence of nucleotide dG-G and dG-MG in DNA is associated with increased mutation frequency, DNA strand breaks and cytotoxicity. Glyoxal (9-26 mM) induced increased mutations and decreased DNA replication. Most mutations were single-base substitutions (48%) with 83% of these occurring at C:G sites. G:C → T:A transversions were predominant, with also some G:C → C:G transversions, G:C → A:T transitions and A:T → T:A transversions. For methylglyoxal (1-10 mM), cytotoxicity and mutation frequency increased with increasing methylglyoxal concentration. Multi-base deletions were predominant (50%), with some base-pair substitutions (35%) where 89% were at C:G sites. Most mutations were G:C → C:G and G:C → T:A transversions. Both glyoxal and methylglyoxal were associated with non-random or hotspot mutation sites /51,52/. The mutagenicity of methylglyoxal was improved markedly in the presence of hydrogen peroxide. This was associated with the formation of *N*₂-acetyl-deoxyguanosine in DNA /53-55/.

The prevention of mutation induced by glyoxal and methylglyoxal by nucleotide excision repair (NER) was investigated by incubation of wild-type and NER-deficient *E. Coli* with glyoxal and methylglyoxal and the *lacI* gene analysed for mutations. Increasing concentration of α-oxoaldehydes led to increased mutations, decreased DNA replication and cell death. Base-pair mutations were higher in the NER-deficient strain relative to the wild-type strain. Most base-pair substitutions were at C:G sites where G:C → T:A transversions were predominant. There were also G:C → A:T transitions and A:T → T:A transversions with glyoxal and TGGC frameshift mutations for methylglyoxal. These studies indicate that nucleotide glycation and its effects are suppressed by NER /56,57/. Introduction of the specific nucleotide AGE CEdG into DNA was also associated with increased mutation frequency and increased DNA strand breaks in *E. coli* /58/.

The formation of crosslinks of protein to DNA by glycation with methylglyoxal has been known for many years /59/. An explanation for this may be crosslinking of the DNA template to the Klenow fragment of DNA polymerase. Methylglyoxal (1 mM) reacted with dG in the DNA template /60/. Glyoxal was much less effective than methylglyoxal in this crosslinking. This may be a very damaging effect of nucleotide glycation although the physiological significance is not yet clear.

Glyoxalase 1 – a critical role in the enzymatic defence against glycation

Accumulation of protein glycation adducts is associated with enzyme inactivation, protein denaturation and a cellular-mediated immune response. Excessive nucleotide glycation is associated with mutagenesis and apoptosis, and excessive lipid glycation with membrane lipid bilayer disruption /17/. In 2003, I developed the concept of an enzymatic defence against glycation protecting against glycation-mediated cell damage. It involves the enzymatic activities that suppress the formation of glycation adducts and repair sites of early glycation: Glo1 and certain aldehyde reductase and dehydrogenase isozymes detoxify reactive carbonyl and α-oxoaldehyde glycating agents (glyoxal, methylglyoxal, 3-deoxyglucosone and others) /61,62/, and amadoriase and fructosamine 3-phosphokinase catalyse the removal of fructosamine glycation adducts formed by glycation of proteins by glucose /63-65/.

The enzymatic defence against glycation suppresses damage to biological macromolecules but it is an imperfect defence; glycation adducts of proteins, nucleotides and basic phospholipids are formed in normal physiological states but at a low level. Steady state levels of glycation adducts are ca. 0.1-1% lysine and arginine residues in proteins, 1 in 10⁵ nucleotides in DNA, and 0.1% basic phospholipids. Protein glycation adducts are removed by proteasomal and lysosomal proteolysis /66,67/. Nucleotide glycation adducts are cleared by nucleotide excision repair /52/, and phospholipid AGEs are removed by lipid turnover /68/. The glycation adducts thereby liberated are eliminated as free glycation adducts (glycated amino acids) in the urine, along with glycation adducts absorbed from food. The enzymatic defence against glycation is overwhelmed in some disease states and glycation adduct concentrations increase – particularly in diabetes and chronic and acute renal failure. There is also a decline of the enzymatic defence against glycation in ageing – particularly expression of Glo1, which may contribute to the pathobiology of ageing /69/. The major mechanism for clearing glycation adducts from the body is by urinary excretion and hence glycation free adducts accumulate profoundly in experimental and clinical uraemia /40,70/. Renal replacement therapy of patients with chronic renal failure with haemodialysis and peritoneal dialysis provides clearance of glycation free adducts in the dialysate /40/.

Oxidative stress is inextricably linked to glycation because the depletion of GSH and NADPH in oxidative stress also decreases the *in situ* activities of Glo1 /71/ and thereby increases the concentrations of glyoxal and methylglyoxal and associated glycation reactions. Glycation of proteins by Glo1 substrates may also increase reactive oxygen species (ROS) – superoxide, hydrogen peroxide and hydroxyl radical, and thereby be a cause or contributory factor to oxidative stress. This is best illustrated by the increased ROS formation associated with mitochondrial dysfunction and methylglyoxal modification of mitochondrial proteins in diabetic nephropathy /72/ and ageing in *Caenorhabditis elegans* /69/.

Glycation contributes to morbidity and mortality of diseases of major social impact (diabetes, heart disease and endstage renal disease) and is suspected to contribute to others (Alzheimer's disease, arthritis and ageing) /17/. Novel therapeutic approaches to prevent the chronic complications of diabetes and improve dialysis therapy in endstage renal disease strive to minimize vascular dysfunction linked to excessive glycation and increase clearance of glycation adducts from the body, respectively /73-75/. Nucleotide glycation is implicated in saccharide-linked mutagenesis and the pharmacological mechanism of cytotoxic antitumour drugs modifying DNA and DNA metabolism.

Overexpression of glyoxalase 1 and multidrug resistance in cancer chemotherapy

The GSH dependent enzyme Glo1 is the major factor involved in the detoxification of glyoxal and methylglyoxal in physiological systems /76/. We developed the first effective inhibitors of Glo1 that had antitumour activity *in vitro* and *in vivo*, *S*-p-bromobenzylglutathione diesters. Addition of these inhibitors to cultured cells led to the cellular accumulation of methylglyoxal, increased nucleotide glycation and induction of apoptosis /15,77-79/. We supplied the diethyl and dicyclopentyl inhibitor derivatives for evaluation against fibroblasts overexpressing Glo1. Evaluation showed that the fibroblasts overexpressing Glo1 were resistant to the Glo1 inhibitor diesters. Remarkably, the cells were also resistant to the anticancer drugs mitomycin C and doxorubicin /80/. This was the first time observation that overexpression of Glo1 may confer multidrug resistance (MDR) to tumours.

Tsuruo and colleagues made a critical observation to link Glo1 with multidrug resistance in cancer chemotherapy. Studies on MDR human monocytic leukaemia UK711 cells and erythroleukaemia K562/ADM cells, using a subtractive hybridisation mRNA approach, showed Glo1 was overexpressed in both cell lines. Moreover, a stable transfectant of Jurkat cells acquired MDR when overexpression of Glo1 was produced. The Glo1 inhibitor SpBrGSHCP₂ /15/ lifted MDR and the cells regained sensitivity to antitumour agents /81/. Human lung cancer NCI-H522 and DMS114 cells with high expression and activity of Glo1 underwent apoptosis when treated with SpBrGSHCP₂. The sensitivity to SpBrGSHCP₂ correlated to the level of Glo1 expression. SpBrGSHCP₂ induced the activation of the stress-activated protein kinases c-Jun NH₂-terminal kinase 1 (JNK1) and p38 mitogen-activated protein kinase (MAPK), which led to caspase activation in Glo1-overexpressing tumour cells. SpBrGSHCP₂ significantly inhibited the growth of xenografted DMS114 and human prostate cancer DU-145 and was the most potent antitumour agent against human tumours overexpression Glo1 – particularly refractory lung and prostate carcinomas /82/. These studies suggest: (i) accumulation of Glo1 substrates are involved in the antitumour activity of important clinical antitumour agents (for example, doxorubicin), and (ii) further development of Glo1 inhibitors may provide antitumour agents active against some of the clinical tumours associated with high incidence and mortality rates (lung and prostate carcinomas). Further support for increased activity in this area of research comes from the link of increased Glo1 expression with invasive ovarian cancer /83/, prostate carcinoma /84/ renal adenocarcinoma /85/ and high expression of Glo1 in human breast cancers /86/ and precancerous lesions /87/.

The link of overexpression of Glo1 with MDR in cancer chemotherapy may involve increased formation of methylglyoxal in response to DNA repair. The cellular response to antitumour drugs that modified DNA or disrupt DNA metabolism is to activate processes of DNA repair, including poly(ADP-ribose) polymerase /88/. This depletes cells of NAD⁺ such that glyceraldehyde-3-phosphate dehydrogenase activity is depleted and triosephosphates, glyceraldehyde-3-phosphate and dihydroxyacetonephosphate, increase markedly /89/. Methylglyoxal is formed mainly by triosephosphate degradation and, hence, a consequent dramatic increase in methylglyoxal formation is expected. The increased methylglyoxal concentrations may modify DNA and protein involved in activation of apoptosis, thereby potentiating the cytotoxic effect of the antitumour agent. This potentiatory effect of methylglyoxal will be blocked by over expression of Glo1. The mechanisms of induction of apoptosis by methylglyoxal is not known although activation of JNK1 and p38 MAPK are involved /82/. Activation of protein kinase C, δ -isoform (PKC δ), was involved in the potentiation of the antitumour effect of cisplatin by methylglyoxal /90/; PKC δ is involved in coordinating cell signalling in response to DNA damage to activate apoptosis, including interaction with hRAD9 and Bcl-2 /91/. Whilst there may be key proteins modified by methylglyoxal that promote apoptosis, the increased DNA damage associated with nucleotide glycation probably also features in apoptotic mechanisms. Deployment of this effectively could provide valuable new antitumour agents.

Physiological regulation of glyoxalase 1 and glycation by glyoxal and methylglyoxal

The modifications of proteins and nucleotides by Glo1 substrates, glyoxal and methylglyoxal, may be viewed as damage to physiological systems. This is suppressed by metabolism of glyoxal and methylglyoxal to glycolate and D-lactate catalysed by the glyoxalase system /2/. There examples emerging, however, of regulation of Glo1 activity in physiological systems that suggests Glo1 substrates and glycation may have a functional role in cell signalling.

Firstly, the high expression and activity of Glo1 in many tumour cells and some micro-organisms /92-94/. This is likely to be linked to the high glycolytic activity of many tumours and some micro-organisms /95/. A high Glo1 activity is required, concomitant with a high flux of methylglyoxal associated with high flux of triosephosphates and anaerobic glycolytic activity, to protect the proteome and genome from functional impairment and mutation, respectively.

Secondly, activation of the receptor for advanced glycation endproducts (RAGE) by S100 proteins found in increased plasma concentration in inflammatory disorders was associated with decreased expression of Glo1. Induction of diabetes in wild type mice decreased the expression of Glo1 whereas induction of diabetes in RAGE (–/–) mice did not /96/. Decreased Glo1 expression leads to increased protein glycation /2/. AGE residues in tissue protein were found co-localized with RAGE. This may be due to RAGE activation by S100 proteins, decreasing the local expression of Glo1 and thereby increasing the local formation of AGE residues. This may be part of an inflammatory response leading to labeling proteins with dicarbonyl-derived hydroimidazolone AGE residues and directing these proteins to the proteasome for destruction. Methylglyoxal modification of proteins is thought to target proteins for proteasomal destruction /97/. If correct, this will link the formation of glyoxal and methylglyoxal-derived AGEs to removal and destruction of proteins, at least for intracellular proteins – a re-interpretation of the role originally attributed to AGEs by Cerami as “signals” on extracellular proteins to target them for cellular uptake and proteolysis /98/.

Thirdly, Glo1 was shown to be phosphorylated and glycation of proteins increased in apoptosis induced by tumour necrosis factor /99/. This, taken together with the overexpression of Glo1 in multidrug resistance in cancer chemotherapy, suggests glyoxal and methylglyoxal may have a role in apoptosis.

These examples of regulation of the Glo1 and cellular concentrations of methylglyoxal-derived glycation is suggestive of a signalling role for methylglyoxal glycation of proteins and nucleotides in physiological systems. The role appears to include influences in malignant transformation /100/, cell death – apoptosis, anoikis (detachment stimulated apoptosis) and eryptosis (erythrocyte programmed cell death) /11,13,79/ and inflammation /101/.

Concluding remarks: emerging evidence that glyoxalase 1 and glycation by glyoxal and methylglyoxal play a critical role in disease and ageing – the tribute to Szent-Gyorgyi

Glycation by glyoxal and methylglyoxal, and the related influence of Glo1, are now emerging as playing a critical role in ageing /69/ and disease processes – vascular complications associated with diabetes /20,41/, renal failure /40,70/, Alzheimer's disease /102,103/ and tumourigenesis and multidrug resistance in cancer chemotherapy /82/. They may also have roles in pathologic anxiety /16,104/, autism /105/, obesity /106/ and other disorders. The abiding tribute to Albert Szent-Gyorgyi is that to the end of his scientific career he studied biological problems of fundamental importance. It is no disrespect to him that the physiological function of methylglyoxal and glyoxalase was left unresolved at the end of his career since over 20 years later we are still struggling to resolve it.

Acknowledgments

I would like to thank the Wellcome Trust (U.K.), Cancer Research UK, Diabetes UK and the Juvenile Diabetes Research Foundation for support for my research, and past and present members of my research team for their contributions to glyoxalase research.

Abbreviations

AGEs	advanced glycation endproducts
Bcl-2	B cell lymphoma/leukemia-2 protein
CEdG	N_2 -(1-carboxyethyl)-deoxyguanosine
CML	N_ϵ -carboxymethyl-lysine
CEL	N_ϵ -carboxyethyl-lysine
CMA	N_ω -carboxymethylarginine
CMdG	N_2 -carboxymethyl-deoxyguanosine
dG	deoxyguanosine
dG-G	3-(2'-deoxyribosyl)-6,7-dihydro-6,7-dihydroxyimidazo[2,3-b]purin-9(8)one
dG-MG	3-(2'-deoxyribosyl)-6,7-dihydro-6,7-dihydroxy-6-methylimidazo-[2,3-b]purine-9(8)one
FL	fructosyl-lysine
GC-MS	gas chromatography with mass spectrometric detection
gdC	5-glycolyldeoxycytidine
G-H1	N_8 -(5-hydro-4-imidazol-2-yl)ornithine
GOLD	bis(lysyl) crosslink derived from glyoxal
Glo1	glyoxalase 1
JNK1	c-Jun NH ₂ -terminal kinase 1
LC-MS/MS	liquid chromatography with tandem mass spectrometric detection
MAPK	mitogen-activated protein kinase
MDR	multidrug resistance
MG-H1	N_8 -(5-hydro-5-methyl-4-imidazol-2-yl)-ornithine
MOLD	bis(lysyl) crosslink derived from methylglyoxal
NER	nucleotide excision repair
PKCδ	protein kinase C, δ -isoform
RAD9	radiation sensitive checkpoint protein and exonuclease
RAGE	receptor for advanced glycation endproducts
ROS	reactive oxygen species
SpBrGSHCp₂	S-p-bromobenzyglutathione cyclopentyl diester

References

1. Szent-Gyorgyi A, Egyud LG, McLaughlin JA. Keto-aldehyde and cell division. *Science*. 1967; 155:539–541. [PubMed: 5333756]
2. Thornalley PJ. Glyoxalase I - structure, function and a critical role in the enzymatic defence against glycation. *Biochem Soc Trans*. 2003; 31:1343–1348. [PubMed: 14641060]
3. Neuberg C. The destruction of lactic aldehyde and methylglyoxal by animal organs. *Biochem Z*. 1913; 49:502–506.
4. Aronsson >A-C, Mannervik B. Characterization of glyoxalase I purified from pig erythrocytes by affinity chromatography. *Biochem J*. 1977; 165:503–509. [PubMed: 921763]
5. Cooper RA. Metabolism of methylglyoxal in microorganisms. *Ann Rev Microbiol*. 1984; 38:49–68. [PubMed: 6093685]
6. Phillips SA, Thornalley PJ. The formation of methylglyoxal from triose phosphates. Investigation using a specific assay for methylglyoxal. *Eur J Biochem*. 1993; 212:101–105. [PubMed: 8444148]
7. Thornalley PJ. The glyoxalase system in health and disease. *Mol Aspects of Med*. 1993; 14:287–371. [PubMed: 8277832]
8. Loidl-Stahlhofen A, Spiteller G. α -Hydroxyaldehydes, products of lipid peroxidation. *Biochim Biophys Acta*. 1994; 1211:156–160. [PubMed: 8117742]
9. Thornalley PJ, Langborg A, Minhas HS. Formation of glyoxal, methylglyoxal and 3-deoxyglucosone in the glycation of proteins by glucose. *Biochem J*. 1999; 344:109–116. [PubMed: 10548540]
10. Selicharova I, Smutna K, Sanda M, et al. 2-DE analysis of a new human cell line EMG3 derived from breast cancer progenitor cells and comparison with normal mammary epithelial cells. *Proteomics*. 2007; 7:1549–1559. [PubMed: 17366476]
11. Dobler D, Ahmed N, Song LJ, Eboigbodin KE, Thornalley PJ. Increased dicarbonyl metabolism in endothelial cells in hyperglycemia induces anoikis and impairs angiogenesis by RGD and GFOGER motif modification. *Diabetes*. 2006; 55:1961–1969. [PubMed: 16804064]
12. Beisswenger PJ, Howell S, Touchette A, Lal S, Szwegold BS. Metformin reduces systemic methylglyoxal levels in type 2 diabetes. *Diabetes*. 1999; 48:198–202. [PubMed: 9892243]
13. Strzinek RA, Scholes VE, Norton SJ. Purification and Characterization of Liver Glyoxalase-I from Normal Mice and from Mice Bearing A Lymphosarcoma. *Cancer Res*. 1972; 32:2359–2364. [PubMed: 4678085]
14. Riboulet-Chavey A, Pierron A, Durand I, Murdaca J, Giudicelli J, Van Obberghen E. Methylglyoxal Impairs the Insulin Signaling Pathways Independently of the Formation of Intracellular Reactive Oxygen Species. *Diabetes*. 2006; 55:1289–1299. [PubMed: 16644685]
15. Thornalley PJ, Edwards LG, Kang Y, et al. Antitumour activity of *S*-*p*-bromobenzylglutathione cyclopentyl diester *in vitro* and *in vivo*. Inhibition of glyoxalase I and induction of apoptosis. *Biochem Pharmacol*. 1996; 51:1365–1372. [PubMed: 8787553]
16. Hovatta I, Tennant RS, Helton R, et al. Glyoxalase 1 and glutathione reductase 1 regulate anxiety in mice. *Nature*. 2005; 438:662–666. [PubMed: 16244648]
17. Thornalley PJ. Clinical significance of glycation. *Clin Lab*. 1999; 45:263–273.
18. Thornalley PJ. Dicarbonyl intermediates in the Maillard reaction. *Ann N Y Acad Sci*. 2005; 1043:111–117. [PubMed: 16037229]
19. Thornalley PJ, Battah S, Ahmed N, et al. Quantitative screening of advanced glycation endproducts in cellular and extracellular proteins by tandem mass spectrometry. *Biochem J*. 2003; 375:581–592. [PubMed: 12885296]
20. Ahmed N, Babaei-Jadidi R, Howell SK, Beisswenger PJ, Thornalley PJ. Degradation products of proteins damaged by glycation, oxidation and nitration in clinical type 1 diabetes. *Diabetologia*. 2005; 48:1590–1603. [PubMed: 15988580]
21. Ahmed N, Argirov OK, Minhas HS, Cordeiro CA, Thornalley PJ. Assay of advanced glycation endproducts (AGEs): surveying AGEs by chromatographic assay with derivatisation by 6-aminoquinolyl-N-hydroxysuccinimidyl-carbamate and application to *N* ϵ -carboxymethyl-lysine- and *N* ϵ -(1-carboxyethyl)lysine-modified albumin. *Biochem J*. 2002; 364:1–14. [PubMed: 11988070]

22. Ahmed N, Thornalley PJ. Chromatographic assay of glycation adducts in human serum albumin glycated *in vitro* by derivatisation with aminoquinolyl-N-hydroxysuccinimidyl-carbamate and intrinsic fluorescence. *Biochem J.* 2002; 364:15–24. [PubMed: 11988071]
23. Odani H, Iijima K, Nakata M, et al. Identification of *N*ω-carboxymethylarginine, a new advanced glycation endproduct in serum proteins of diabetic patients: possibly a new marker of aging and diabetes. *Biochem Biophys Res Comm.* 2001; 285:1232–1236. [PubMed: 11478788]
24. Shipanova IN, Glomb MA, Nagaraj RH. Protein modification by methylglyoxal: chemical nature and synthetic mechanism of a major fluorescent adduct. *Arch Biochem Biophys.* 1997; 344:29–36. [PubMed: 9244378]
25. Ahmed N, Dobler D, Dean M, Thornalley PJ. Peptide mapping identifies hotspot site of modification in human serum albumin by methylglyoxal involved in ligand binding and esterase activity. *J Biol Chem.* 2005; 280:5724–5732. [PubMed: 15557329]
26. Ahmed N, Thornalley PJ, Dawczynski J, et al. Methylglyoxal-derived hydroimidazolone advanced glycation endproducts of human lens proteins. *Invest Ophth Vis Sci.* 2003; 44:5287–5292.
27. Haik JR GM, Lo TWC, Thornalley PJ. Methylglyoxal concentration and glyoxalase activities in human lens. *Exp Eye Res.* 1994; 59:497–500. [PubMed: 7859825]
28. Verzijl N, DeGroot J, Thorpe SR, et al. Effect of collagen turnover on the accumulation of advanced glycation endproducts. *J Biol Chem.* 2000; 275:39027–39031. [PubMed: 10976109]
29. Wells-Knecht MC, Lyons TJ, McCance DR, Thorpe SR, Baynes JW. Age-dependent increases in ortho-tyrosine and methionine sulfoxide in human skin collagen is not accelerated in diabetes. *J Clin Invest.* 1997; 100:839–846. [PubMed: 9259583]
30. Goldberg AL. Protein degradation and protection against misfolded or damaged proteins. *Nature.* 2003; 426:895–899. [PubMed: 14685250]
31. Gerner C, Vejda S, Gelbmann D, et al. Concomitant determination of absolute values of cellular protein amounts, synthesis rates, and turnover rates by quantitative proteome profiling. *Mol Cell Proteomics.* 2002; 1:528–537. [PubMed: 12239281]
32. Henle T. AGEs in foods: Do they play a role in uremia? *Kidney Int.* 2003; 63:S145–S147.
33. Ahmed N, Mirshekar-Syahkal B, Kennish L, Karachalias N, Babaei-Jadidi R, Thornalley PJ. Assay of advanced glycation endproducts in selected beverages and food by liquid chromatography with tandem mass spectrometric detection. *Mol Nutr & Food Res.* 2005; 49:691–699. [PubMed: 15945118]
34. Oste RE, Miller R, Sjostrom H, Noren O. Effect of Maillard Reaction-Products on Protein Digestion - Studies on Pure Compounds. *J Agric Food Chem.* 1987; 35:938–942.
35. Ahmed N, Thornalley PJ, Luthen R, et al. Processing of protein glycation, oxidation and nitrosation adducts in the liver and the effect of cirrhosis. *J Hepatol.* 2004; 41:913–919. [PubMed: 15582123]
36. Thornalley PJ. Glycation free adduct accumulation in renal disease: the new AGE. *Pediatr Nephrol.* 2005; 20:1515–1522. [PubMed: 16133053]
37. Ahmed MU, Brinkmann Frye E, Degenhardt TP, Thorpe SR, Baynes JW. N^ε-(Carboxyethyl)lysine, a product of chemical modification of proteins by methylglyoxal, increases with age in human lens proteins. *Biochem J.* 1997; 324:565–570. [PubMed: 9182719]
38. DeGroot J, Verzijl N, Wenting-Van Wijk MJG, et al. Age-related decrease in susceptibility of human articular cartilage to matrix metalloproteinase-mediated degradation - The role of advanced glycation end products. *Arthritis Rheum.* 2001; 44:2562–2571. [PubMed: 11710713]
39. Gallet X, Charlotiaux B, Thomas A, Brasseur R. A fast method to predict protein interaction sites from sequences. *J Mol Biol.* 2000; 302:917–926. [PubMed: 10993732]
40. Agalou S, Ahmed N, Babaei-Jadidi R, Dawnay A, Thornalley PJ. Profound mishandling of protein glycation degradation products in uremia and dialysis. *J Am Soc Nephrol.* 2005; 16:1471–1485. [PubMed: 15800128]
41. McLellan AC, Thornalley PJ, Benn J, Sonksen PH. The glyoxalase system in clinical diabetes mellitus and correlation with diabetic complications. *Clin Sci.* 1994; 87:21–29. [PubMed: 8062515]

42. Mann VM, Tucker B, Thornalley PJ, Dawnay A. Elevated plasma methylglyoxal and glyoxal in uraemia: implications for advanced glycation endproduct formation. *Kidney Int.* 1999; 55:2582–2582.
43. Segal MS, Bihorac A, Koc M. Circulating endothelial cells: tea leaves for renal disease. *Am J Physiol-Renal.* 2002; 283:F11–F19.
44. Tajika T, Bando I, Furuta T, Moriya N, Koshino H, Uramoto M. Novel amino acid metabolite produced by *Streptomyces* sp.: taxonomy, isolation and structural elucidation. *Biosci Biotechnol Biochem.* 1997; 61:1007–1010. [PubMed: 9214763]
45. Bechtold U. Evidence of advanced glycation endproducts, oxidation and nitrosation damage in *Arabidopsis* leaves. *Comp Biochem Physiol A.* 2007; 146:S56–S56.
46. Kasai H, Iwamoto-Tanaka N, Fukada S. DNA modifications by the mutagen glyoxal: adduction to G and C, deamination of C and GC and GA crosslinking. *Carcinogenesis.* 1998; 19:1459–1465. [PubMed: 9744543]
47. Schneider M, Quistad GB, Casida JE. $N^{2,7}$ -Bis(1-hydroxy-2-oxopropyl)-2'-deoxyguanosine: identical noncyclic adducts with 1,3-dichloropropene epoxides and methylglyoxal. *Chem Res Toxicol.* 1998; 11:1536–1542. [PubMed: 9860499]
48. Papoulis A, Al-Abed Y, Bucala R. Identification of N^2 -(1-carboxyethyl)guanine (CEG) as a guanine advanced glycosylation endproduct. *Biochemistry.* 1995; 34:648–655. [PubMed: 7819260]
49. Fleming T, Rabbani N, Thornalley PJ. Quantitative Screening of DNA Biomarkers of Glycation and Oxidation. *Ann N Y Acad Sci.* 2007 in press.
50. Seidel W, Pischetsrieder M. DNA glycation leads to depurination by the loss of N^2 -carboxyethylguanine *in vitro*. *Cell Mol Biol.* 1998; 44:1165–1170. [PubMed: 9846899]
51. Murata-Kamiya N, Kamiya H, Kaji H, Kasai H. Glyoxal, a major product of DNA oxidation, induces mutations at G:C sites on a shuttle vector plasmid replicated in mammalian cells. *Nucleic Acids Res.* 1997; 25:1897–1902. [PubMed: 9115355]
52. Murata-Kamiya N, Kamiya H, Kaji H, Kasai H. Methylglyoxal induces G:C to C:G and G:C to T:A transversions in the *supF* gene on a shuttle vector plasmid replicated in mammalian cells. *Mutat Res.* 2000; 468:173–182. [PubMed: 10882894]
53. Nukaya H, Iwami H, Ishida H, et al. N^2 -Acetylation of 2'-deoxyguanosine by coffee mutagens, methylglyoxal and hydrogen peroxide. *Mutat Res.* 1990; 245:251–257. [PubMed: 2266977]
54. Nukaya H, Inaoka Y, Ishida H, et al. Modification of the amino group of guanosine by methylglyoxal and other D-ketoaldehydes in the presence of H_2O_2 . *Chem Pharm.* 1993; 41:649–653.
55. Tada A, Wakabayashi K, Totsuba Y, Sugimura T, Tsuji K, Nukaya H. ^{32}P -Postlabelling analysis of a DNA adduct, an N^2 -acetyl derivative of guanine, formed *in vitro* by methylglyoxal and hydrogen peroxide in combination. *Mutat Res.* 1996; 351:173–180. [PubMed: 8622711]
56. Murata-Kamiya N, Kamiya H, Kaji H, Kasai H. Nucleotide excision repair proteins may be involved in the fixation of glyoxal-induced mutagenesis in *Escherichia Coli*. *Biochem Biophys Res Commun.* 1998; 248:412–417. [PubMed: 9675151]
57. Murata-Kamiya N, Kaji H, Kasai H. Deficient nucleotide excision repair increases base-pair substitutions but decreases TGGC frameshifts induced by methylglyoxal in *Escherichia coli*. *Mutat Res.* 2000; 442:19–28. [PubMed: 10366769]
58. Pischetsrieder M, Seidel W, Munch G, Schinzel R. N^2 -(1-Carboxyethyl)deoxyguanosine, a nonenzymatic glycation adduct of DNA, induces single strand breaks and increases mutation frequencies. *Biochem Biophys Res Commun.* 1999; 264:544–549. [PubMed: 10529399]
59. Brambilla G, Sciaba L, Faggini P, Finollo R, Bassi AM. Methylglyoxal-induced DNA-protein cross-links and cytotoxicity in chinese hamster ovary cells. *Carcinogenesis.* 1985; 6:683–686. [PubMed: 4006054]
60. Murata-Kamiya N, Kamiya H. Methylglyoxal, an endogenous aldehyde, crosslinks DNA polymerase and the substrate DNA. *Nucleic Acids Res.* 2001; 29:3433–3438. [PubMed: 11504881]
61. Shinohara M, Thornalley PJ, Giardino I, et al. Overexpression of glyoxalase I in bovine endothelial cells inhibits intracellular advanced glycation endproduct formation and prevents hyperglycaemia-

- induced increases in macromolecular endocytosis. *J Clin Invest.* 1998; 101:1142–1147. [PubMed: 9486985]
62. Suzuki K, Koh YH, Mizuno H, Hamaoko R, Taniguchi N. Overexpression of aldehyde reductase protects PC12 cells from the cytotoxicity of methylglyoxal or 3-deoxyglucosone. *J Biochem.* 1998; 123:353–357. [PubMed: 9538214]
 63. Takahashi M, Pischetsrieder M, Monnier VM. Isolation, purification, and characterization of Amadoriase isoenzymes (fructosyl amine-oxygen oxidoreductase EC 1.5.3) from *Aspergillus sp.* *J Biol Chem.* 1997; 272:3437–3443. [PubMed: 9013588]
 64. Delpierre G, Rider MH, Collard F, et al. Identification, cloning, and heterologous expression of a mammalian fructosamine-3-kinase. *Diabetes.* 2000; 49:1627–1634. [PubMed: 11016445]
 65. Swergold BS, Howell S, Beisswenger PJ. Human fructosamine-3-kinase. Purification, sequencing, substrate specificity, and evidence of activity in vivo. *Diabetes.* 2001; 50:2139–2147. [PubMed: 11522682]
 66. Michalek MT, Grant EP, Rock KL. Chemical denaturation and modification of ovalbumin alters its dependence on ubiquitin conjugation for class I antigen presentation. *J Immunol.* 1996; 157:617–624. [PubMed: 8752909]
 67. Westwood ME, Argirov OK, Abordo EA, Thornalley PJ. Methylglyoxal-modified arginine residues - a signal for receptor-mediated endocytosis and degradation of proteins by monocytic THP-1 cells. *Biochim Biophys Acta.* 1997; 1356:84–94. [PubMed: 9099994]
 68. Requena JR, Ahmed MU, Fountain CW, et al. Carboxymethylethanolamine, a biomarker of phospholipid modification during the Maillard reaction *in vivo*. *J Biol Chem.* 1997; 272:17473–17479. [PubMed: 9211892]
 69. Morcos M, Du XL, Hutter AASH, et al. Life extension in *Caenorhabditis elegans* by overexpression of glyoxalase I - The connection to protein damage by glycation, oxidation and nitration. *Free Radical Res.* 2005; 39:S43–S43.
 70. Rabbani N, Sebekova K, Sebekova K Jr, Heidland A, Thornalley PJ. Protein glycation, oxidation and nitration free adduct accumulation after bilateral nephrectomy and ureteral ligation. *Kidney Int.* 2007 in press.
 71. Abordo EA, Minhas HS, Thornalley PJ. Accumulation of α -oxoaldehydes during oxidative stress. A role in cytotoxicity. *Biochem Pharmacol.* 1999; 58:641–648. [PubMed: 10413301]
 72. Rosca MG, Mustata TG, Kinter MT, et al. Glycation of mitochondrial proteins from diabetic rat kidney is associated with excess superoxide formation. *Am J Physiol Renal.* 2005; 289:F420–F430.
 73. Hammes H-P, Du X, Edelstein D, et al. Benfotiamine blocks three major pathways of hyperglycemic damage and prevents experimental diabetic retinopathy. *Nat Med.* 2003; 9:294–299. [PubMed: 12592403]
 74. Babaei-Jadidi R, Karachalias N, Ahmed N, Battah S, Thornalley PJ. Prevention of incipient diabetic nephropathy by high dose thiamine and Benfotiamine. *Diabetes.* 2003; 52:2110–2120. [PubMed: 12882930]
 75. Dawnay A, Millar DJ. The pathogenesis and consequences of AGE formation in uraemia and its treatment. *Cell Mol Biol.* 1998; 44:1081–1094. [PubMed: 9846890]
 76. Thornalley PJ. Pharmacology of methylglyoxal: formation, modification of proteins and nucleic acids, and enzymatic detoxification - a role in pathogenesis and antiproliferative chemotherapy. *General Pharmac.* 1996; 27:565–573.
 77. Lo TWC, Thornalley PJ. Inhibition of proliferation of human leukemia 60 cells by diethyl esters of glyoxalase inhibitors *in vitro*. *Biochem Pharmacol.* 1992; 44:2357–2363. [PubMed: 1472100]
 78. Thornalley PJ, Ladan MJ, Ridgway SJS, Kang Y. Antitumour activity of S-p-bromobenzylglutathione diesters *in vitro*: a structure activity study. *J Med Chem.* 1996; 39:3409–3411. [PubMed: 8765525]
 79. Kang Y, Edwards LG, Thornalley PJ. Effect of methylglyoxal on human leukaemia 60 cell growth: modification of DNA, G₁ growth arrest and induction of apoptosis. *Leukemia Res.* 1996; 20:397–405. [PubMed: 8683979]
 80. Ranganathan S, Walsh ES, Tew KD. Glyoxalase I in detoxification: studies using a glyoxalase I transfectant cell line. *Biochem J.* 1995; 309:127–131. [PubMed: 7619046]

81. Sakamoto H, Mashima T, Kazaki A, et al. Glyoxalase I is involved in resistance of human leukemia cells to antitumour agent-induced apoptosis. *Blood*. 2000; 95:3214–3218. [PubMed: 10807791]
82. Sakamoto H, Mashima T, Sato S, Hashimoto Y, Yamori T, Tsuruo T. Selective activation of apoptosis program by *S*-p-bromobenzylglutathione cyclopentyl diester in glyoxalase I-overexpressing human lung cancer cells. *Clin Cancer Res*. 2001; 7:2513–2518. [PubMed: 11489834]
83. Jones MB, Krutzsch H, Shu H, et al. Proteomic analysis and identification of new biomarkers antihypertherapeutic agents for invasive ovarian cancer. *Proteomics*. 2002; 2:78–84.
84. Samadi AA, Fullerton SA, Tortorello DG, et al. Glyoxalase I phenotype as a potential risk factor for prostate carcinoma. *Urology*. 2001; 57:183–187. [PubMed: 11164178]
85. Dunn SR, Qi ZH, Bottinger EP, Breyer MD, Sharma K. Utility of endogenous creatinine clearance as a measure of renal function in mice. *Kidney Int*. 2004; 65:1959–1967. [PubMed: 15086941]
86. Rulli A, Carli L, Romani R, et al. Expression of glyoxalase I and II in normal and breast cancer tissues. *Breast Cancer Res Tr*. 2001; 66:67–72.
87. Carlson EC, Audette JL, Klevay LM, Nguyen H, Epstein PN. Ultrastructural and functional analyses of nephropathy in calmodulin-induced diabetic transgenic mice. *Anat Rec*. 1997; 247:9–19. [PubMed: 8986297]
88. Lautier D, Lagueur J, Thibodeau J, Menard L, Poirier GG. Molecular and biochemical features of poly(ADP-ribose) metabolism. *Mol Cell Biochem*. 1993; 122:171–193. [PubMed: 8232248]
89. Ronen SM, DiStefano F, McCoy CL, et al. Magnetic resonance detects metabolic changes associated with chemotherapy-induced apoptosis. *Brit J Cancer*. 1999; 80:1035–1041. [PubMed: 10362112]
90. Godbout JP, Pesavento J, Hartman ME, Manson SR, Freund GG. Methylglyoxal enhances cisplatin-induced cytotoxicity by activating protein kinase C delta. *J Biol Chem*. 2002; 277:2554–2561. [PubMed: 11707430]
91. Yoshida K, Wang HG, Miki Y, Kufe D. Protein kinase C delta is responsible for constitutive and DNA damage-induced phosphorylation of Rad9. *EMBO J*. 2003; 22:1431–1441. [PubMed: 12628935]
92. Ayoub FM, Zaman MA, Thornalley PJ, Masters JRW. Glyoxalase activity in human tumour cell lines *in vitro*. *Anticancer Res*. 1993; 13:151–156. [PubMed: 8476206]
93. Thornalley PJ. Advances in glyoxalase research. Glyoxalase expression in malignancy, anti-proliferative effects of methylglyoxal, glyoxalase I inhibitor diesters and *S*-D-lactoylglutathione, and methylglyoxal-modified protein binding and endocytosis by the advanced glycation endproduct receptor. *Crit Rev Oncol Hematol*. 1995; 20:99–128. [PubMed: 7576201]
94. Vander Jagt DL. d-Lactate production in erythrocytes infected with *Plasmodium falciparum*. *Mol Biochem Parasitol*. 1990; 42:277–284. [PubMed: 2270109]
95. Dills WL. Nutritional and physiological consequences of tumour glycolysis. *Parasitology*. 1993; 107:S177–S186. [PubMed: 8115182]
96. Bierhaus A, Stoyanov S, Haag GM, et al. RAGE-deficiency reduces diabetes-associated impairment of glyoxalase-I in neuronal cells. *Diabetes*. 2006; 55:A511–A511.
97. Du J, Zeng J, Ou X, Ren X, Cai S. Methylglyoxal downregulates Raf-1 protein through a ubiquitination-mediated mechanism. *Int J Biochem Cell Biol*. 2006; 38:1084–1091. [PubMed: 16504566]
98. Cerami A. Aging of proteins and nucleic acids: what is the role of glucose? *Trends Biochem Sci*. 1986; 11:311–314.
99. van Herreweghe F, Mao J, Chaplen FWR, et al. Tumour necrosis factor-induced modulation of glyoxalase I activities through phosphorylation by PKA results in cell death and is accompanied by the formation of a specific methylglyoxal-derived AGE. *Proc Natl Acad Sci USA*. 2002; 99:949–954. [PubMed: 11792832]
100. Thornalley PJ. Protecting the genome: defence against nucleotide glycation and emerging role of glyoxalase I over expression in multidrug resistance in cancer chemotherapy. *Biochem Soc Trans*. 2003; 31:1372–1377. [PubMed: 14641066]

101. Bierhaus A, Konrade I, Haag GM, et al. The receptor RAGE regulates glyoxalase-1 transcription, expression and activity. *Diabetologia*. 2005; 48:A90–A90.
102. Chen F, Wollmer MA, Hoerndli F, et al. Role for glyoxalase I in Alzheimer's disease. *Proc Natl Acad Sci USA*. 2004; 101:7687–7692. [PubMed: 15128939]
103. Ahmed N, Ahmed U, Thornalley PJ, Hager K, Fleischer GA, Munch G. Protein glycation, oxidation and nitration marker residues and free adducts of cerebrospinal fluid in Alzheimer's disease and link to cognitive impairment. *J Neurochem*. 2004; 92:255–263. [PubMed: 15663474]
104. Thornalley PJ. Unease on the role of glyoxalase 1 in high-anxiety-related behaviour. *Trends in Mol Medicine*. 2006; 12:195–199.
105. Junaid MA, Kowal D, Barua M, Pullarkat PS, Brooks SS, Pullarkat RK. Proteomic studies identified a single nucleotide polymorphism in glyoxalase I as autism susceptibility factor. *Am J Med Genet*. 2004; 131A:11–17. [PubMed: 15386471]
106. Kumar KG, Poole AC, York B, Volaufova J, Zuberi A, Richards BKS. Quantitative trait loci for carbohydrate and total energy intake on mouse chromosome 17: congenic strain confirmation and candidate gene analyses (Glo1, Glp1r). *American Journal of Physiology-Regulatory Integrative and Comparative Physiology*. 2007; 292:R207–R216.
107. Cordeiro C, Ponces Freire A. Methylglyoxal assay in cells as 2-methylquinoxaline using 1,2-diaminobenzene as derivatising reagent. *Anal Biochem*. 1996; 234:221–224. [PubMed: 8714602]
108. Beisswenger BGK, Delucia EM, Lapoint N, Sanford RJ, Beisswenger PJ. Ketosis Leads to Increased Methylglyoxal Production on the Atkins Diet. *Ann N Y Acad Sci*. 2005; 1043:201–210. [PubMed: 16037240]
109. McLellan AC, Phillips SA, Thornalley PJ. The assay of methylglyoxal in biological systems by derivatization with 1,2-diamino-4,5-dimethoxybenzene. *Anal Biochem*. 1992; 206:17–23. [PubMed: 1456430]
110. Espinosa-Mansilla A, Duran-Meras I, Salinas F. High-Performance Liquid Chromatographic-Fluorometric Determination of Glyoxal, Methylglyoxal, and Diacetyl in Urine by Prederivatization to Pteridinic Rings. *Anal Biochem*. 1998; 255:263–273. [PubMed: 9451513]
111. Thornalley PJ, Yurek-George A, Argirov OK. Kinetics and mechanism of the reaction of aminoguanidine with the α -oxoaldehydes, glyoxal, methylglyoxal and 3-deoxyglucosone under physiological conditions. *Biochem Pharmacol*. 2000; 60:55–65. [PubMed: 10807945]
112. Maeta K, Izawa S, Okazaki S, Kuge S, Inoue Y. Activity of the Yap1 Transcription Factor in *Saccharomyces cerevisiae* Is Modulated by Methylglyoxal, a Metabolite Derived from Glycolysis. *Mol Cell Biol*. 2004; 24:8753–8764. [PubMed: 15367692]

Figure 1.
The glyoxalase system and metabolism of methylglyoxal.

Figure 2.

a. Advanced glycation endproducts residues formed from glyoxal and methylglyoxal with (a) proteins and (b) nucleotides. In (a), protein AGEs are shown as AGE residues with the peptide backbone –CO–CHR–NH– shown on the left. In (b), nucleotide AGEs are shown as nucleic acid base modifications with the 3-(2'-deoxyribose) moiety omitted for clarity and linkage indicated by the dashed link.

Figure 3. Biodistribution scheme illustrating flows of formation and removal of protein glycation free adducts.

Table 1Methods for quantifying glyoxal, methylglyoxal and other α,β -dicarbonyls in physiological systems

Derivatising agent	Advantages	Disadvantages	Reference
1,2-Diaminobenzene (HPLC with spectrophotometric detection)	High reactivity at low pH (also at neutral and high pH). Available commercially in high purity (also some analyte standard adducts). Good adduct stability.	Poor sensitivity – for HPLC with spectrophotometric detection. 1,2-Diaminobenzene degrades oxidatively to form glyoxal and methylglyoxal. Interferences.	/107/
1,2-Diaminobenzene (GC-MS)	As above. High sensitivity and specific detection.		/108/
1,2-Diaminobenzene (LC-MS/MS)	As above. High sensitivity and specific detection.	Interferences controlled. Limits of detection: glyoxal 0.21 pmol and methylglyoxal 0.25 pmol.	/11/
1,2-Diamino-4,5-dimethoxybenzene	High sensitivity. High reactivity at low pH. Good adduct stability.	Highly unstable derivatising agent - degrades oxidatively to form glyoxal and methylglyoxal. Not available commercially in high purity.	/109/
6-Hydroxy-2,4,5-triaminopyrimidine	Available commercially in high purity (also some analyte standard adducts). Derivatisation at low – neutral pH.	High temperature required for derivatisation (60 °C, 45 min). Interferences.	/110/
Aminoguanidine	High reactivity at neutral and high pH. Available commercially in high purity (also some analyte standard adducts). Good analyte stability.	Difficult to detect adducts. Two isomeric adducts (except glyoxal) Interference: triosephosphates and degrading sugars.	/111/
Glutathione/ glyoxalase 1	Enzymatic reaction.	Poor sensitivity. Poor adduct stability. Inappropriate boiling of samples.	/112/